Application of AI in Hypertension Health Education: Scoping Review

• by Haoran Chen, Shenglan Xiao, Tong Wan, Gui Li, Yanhong Peng, Zhimin Wang

• July 15, 2026

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

• by Kathryn Wighton

• July 16, 2026

• 6 min

A two-phase machine learning framework for coronary heart disease risk prediction: Integrating population ecology with individual pathophysiology

• by Lin Yang, Jing Guo, Junwei Xu

• July 7, 2026

Editorial: Clinical Trials in Cardiovascular Medicine: 2025 — Addressing Residual Cardiovascular Risks Through Precision-Guided Approaches

• by Wang, Euscia Y, XU, KEMAN, Shao, Ying, Lu, Yifan, Hung, Shih yu, Yuan, Bo, Xiang, Haiyan, Wang, Hong, Yang, MD, PhD, Professor Xiaofeng

• July 2, 2026